Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia.

Chandra IS, Kumar KL, Reddy MP, Reddy CM.

Indian J Psychol Med. 2014 Jul;36(3):294-8. doi: 10.4103/0253-7176.135383.

3.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
4.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
5.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
6.

Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.

Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW.

J Clin Psychiatry. 2004 Sep;65(9):1211-8.

PMID:
15367047
7.

A study of reasons of non-compliance of psychiatric treatment and patients' attitudes towards illness and treatment in Qatar.

Bener A, Dafeeah EE, Salem MO.

Issues Ment Health Nurs. 2013 Apr;34(4):273-80. doi: 10.3109/01612840.2012.745039.

PMID:
23566190
8.

Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.

Stanković Z, Britvić D, Vuković O, Ille T.

Psychiatr Danub. 2008 Mar;20(1):42-52.

PMID:
18376330
9.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241
10.
11.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

12.

How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R.

Psychiatry Res. 2011 May 15;187(1-2):55-61. doi: 10.1016/j.psychres.2010.10.012. Epub 2010 Nov 12.

PMID:
21074860
13.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
14.

Analysis of variables affecting drug compliance in schizophrenia.

Ansari S, Mulla S.

Ind Psychiatry J. 2014 Jan;23(1):58-60. doi: 10.4103/0972-6748.144968.

15.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
16.

Indicators of medication compliance in first-episode psychosis.

Kampman O, Laippala P, Väänänen J, Koivisto E, Kiviniemi P, Kilkku N, Lehtinen K.

Psychiatry Res. 2002 May 15;110(1):39-48.

PMID:
12007592
17.

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA.

Schizophr Bull. 2009 Mar;35(2):336-46. doi: 10.1093/schbul/sbn067. Epub 2008 Jun 26.

18.

Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.

Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW.

Pharmacopsychiatry. 2004 May;37(3):103-9.

PMID:
15138893
19.

Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors.

Agarwal MR, Sharma VK, Kishore Kumar KV, Lowe D.

Int J Soc Psychiatry. 1998 Summer;44(2):92-106.

PMID:
9675629
20.

Schizophrenia and the efficacy of qEEG-guided neurofeedback treatment: a clinical case series.

Surmeli T, Ertem A, Eralp E, Kos IH.

Clin EEG Neurosci. 2012 Apr;43(2):133-44. doi: 10.1177/1550059411429531. Epub 2012 Mar 27.

PMID:
22715481
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk